{‘She has zero qualifications’: the American scientific establishment braces for Dr. Høeg's tenure at the Food and Drug Administration.

While the US proceeds with sweeping changes to its vaccination recommendations, one figure has surfaced in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on Covid shots during the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her short position at the FDA.

Proposed Shifts to Pediatric Immunization Program

Public health authorities planned to unveil radical revisions to the childhood vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US at odds with much of the international standard with little proof for benefit. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Dr. Høeg is listed to address the audience at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting some pediatric vaccine recommendations in the US to become more like Denmark, a nation with universal health coverage and a citizenry about the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – usually the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Background

Dr. Høeg has no apparent experience in medication creation, regulation or administrative roles, which has been typical for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Past commissioners of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who led CBER have had.”

This division has an vast range of responsibilities at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the generic program authorizes numerous generic drugs. There is also a biologic copycat branch, non-prescription drug unit and more, and each of these need to be supervised,” Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a major management element to the role, which supervises in excess of 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” the former official added.

Official Statement and Controversial Programs

Regarding concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns are based on incorrect premises”.

“Her experience aligns with the responsibilities of her job,” the official said, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed expedited medication authorization process that apparently concerned her former heads. “By what process are these medications being picked for this fast-track system? Who makes the choices?” Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards less stringent regulations of most medications, aside from shots.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, track record, Howard said. She published a analysis using non-validated volunteer-provided data to estimate the rate of heart inflammation after COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership featured revising regulations for new vaccines and discontinuing “non-essential” vaccines, she stated after the election on a online show. At the FDA, Høeg has reportedly proposed preventing adolescent males from getting COVID-19 vaccinations.

“She’s an all-around true believer who commences with her preconceived notions and tailors the evidence to retrofit the science in a very disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|